LUMO Overview

Appointment of Dr. Emmett T. Cunningham: Aviceda Therapeutics has appointed Dr. Emmett T. Cunningham Jr. to its Board of Directors, bringing over 20 years of experience in medicine and investment, particularly in ophthalmology, which will aid the company's advancement of its immunomodulatory candidate AVD-104.

Overview of AVD-104 and Company Goals: Aviceda is focused on developing its HALOS™ nanotechnology platform and AVD-104 for treating geographic atrophy due to age-related macular degeneration, with a broader pipeline targeting various therapeutic areas including immunology and oncology.

Lumos Pharma Tender Offer Completion: Lumos Pharma successfully completed a tender offer for its shares at $4.25 each, resulting in the acquisition of approximately 75.62% of its outstanding shares by Double Point Ventures (DPV), allowing DPV to finalize the merger without additional stockholder votes.

Post-Merger Operations: Following the merger, Lumos Pharma will operate as a standalone business under DPV from Austin, Texas, with its common stock ceasing to trade on NASDAQ and shareholders receiving cash and contingent value rights for their un-tendered shares.

Lumos Pharma's Clinical Trials: Lumos Pharma presented new data from its Phase 2 clinical trials for LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD), at the ESPE 2024 meeting, showing sustained growth and significant increases in height velocity and hormone levels over 24 months.

Future Developments: The company plans to advance LUM-201 into a Phase 3 clinical trial next year, aiming to transform the growth hormone market from injectable to oral therapies.

Investigation of Companies: Halper Sadeh LLC is investigating Lumos Pharma, Kidpik Corp., and Outbrain Inc. for potential violations of federal securities laws and breaches of fiduciary duties related to their recent transactions, including sales and mergers.

Shareholder Rights: The law firm encourages shareholders from these companies to contact them for legal rights and options, offering representation on a contingent fee basis without upfront costs.

Class Action Firm Overview: Monteverde & Associates PC, recognized as a top firm for shareholder recovery, is investigating several proposed mergers involving Outbrain Inc., Lumos Pharma Inc., Kidpik Corp., and Southport Acquisition Corporation, with shareholder votes scheduled for December 2024.

Legal Services Offered: The firm emphasizes its successful track record in recovering money for shareholders and invites individuals with concerns about the mentioned companies to contact them for free information.